Gene Mutation Spectrum of Thalassemia Among Children in Yunnan Province

Ti-Long Huang, Tian-Yao Zhang, Chun-Yan Song, Yun-Bi Lin, Bao-Hua Sang, Qing-Ling Lei, Yu Lv, Chun-Hui Yang, Na Li, Xin Tian, Yue-Huang Yang* and Xian-Wen Zhang*

1 Department of Hematology, Kunming Children’s Hospital, Kunming, China, 2 Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China, 3 Medical Faculty, Kunming University of Science and Technology, Kunming, China

Background: Thalassemia is an autosomal genetic disorder, found throughout the world. It is still not treatable and create socio economic problems. In this study, we investigated the prevalence and spectrum features of thalassemia in Yunnan Province, the southwestern area of China. During 2014–2018, a total of 3,539 suspected thalassemia children were detected with α- and β-thalassemia mutations by gap-Polymerase Chain Reaction (PCR) and reverse dot blot (RDB) analysis in Kunming Children’s Hospital.

Results: Of these patients, 1,130 were diagnosed thalassemia gene carriers with a carrying rate of 31.92%. Among them, α-thalassemia was 43.63%, β-thalassemia was 53.98%, cases with both α- and β- thalassemia was 2.39%. In α-thalassemia patients, the most common mutations was –SEA/αα (52.13%), followed by –α3.7/αα (27.79%), hemoglobin H disease (18.46%), and –α4.2/αα (1.62%). Fifteen gene mutations and 30 genotypes were identified in β-thalassemia patients, with the five most common mutations CD17 (A>T) (29.51%), CD41–42 (–TTCT) (27.87%), IVS-II-654 (C>T) (14.92%), CD26 (G>A) (6.89%), and CD26/CD27 (2.62%) accounting for 81.81% of the β-globin gene mutations. Furthermore, we found two rare mutations CD34 (TGG → TAG) and Int in Chinese populations.

Conclusions: Our results suggested that the prevalence and gene mutation spectrum of thalassemia display obviously heterogeneity among children in Yunnan Province. The findings provide the valuable information for premarital and pre-pregnancy screening, prenatal diagnostic services, and designing appropriate prevention programs to control thalassemia for future in this area.

Keywords: thalassemia, gene mutation spectrum, children, Yunnan province, China

INTRODUCTION

Thalassemia is an inherited autosomal recessive disease resulting from mutations in the α- and β-globin gene clusters on chromosome 16 and chromosome 11, respectively. It is characterized by the absence or reduced synthesis of globin chains of hemoglobin and includes two main types, α- and β- thalassemia (1, 2). It is reported thalassemia is one of the top five kinds of major birth
defects (3). To date, there is no ideal treatment for patients with thalassemia major, except bone marrow transplantation (4). Thalassemia major has imposed an enormous burden on society and has serious impact on the quality of life of the population (5).

High prevalence of thalassemia was mainly reported in southern China, Southeast Asia, India, the Middle East, Africa and Mediterranean region (6). However, population in different regions has their own spectrums of thalassemia (7). At present, it is reported thalassemia is widely distributed on the southern China, particularly in the provinces of Guangdong (8), Guangxi (9), and Hainan (10). Yunnan which have a high frequency of thalassemia is located in the southwestern of China at the junction of Guangxi, Guizhou, and Sichuan provinces (11). However, only few studies reported the prevalence and distribution pattern of α- and β-thalassemia in Yunnan provinces, especially in children. This study is the first large-scale investigate to analyze the prevalence and mutations features of thalassemia children in Yunnan Province.

MATERIALS AND METHODS

Subjects
A total of 3,539 children who were suspected of thalassemia were recruited and tested (male 1,843, female 1,696, age range from 0 to 10 years) from January 2014 to December 2018 in Kunming Children’s Hospital, Yunnan, China. The study has been approved by the Ethic Committee of Kunming Children’s Hospital. Consent forms were signed by the parents.

Hematological Analysis
Peripheral venous blood (5 mL) was collected into an EDTA anticoagulated tube. Peripheral blood counts and red blood cell indices were determined using the automatic blood cell analyzer (Kobe, Japan).

The children with low mean corpuscular volume (MCV) values (<82 fl) or low mean cell hemoglobin (MCH) values (<27 pg) were considered possible carriers of thalassemia (12).

Hemoglobin electrophoresis was used to analyze the percent of hemoglobin Hbs A, A2, F, and any abnormal hemoglobin variant. The children with low HbA2 (<2.5%) values were considered possibly α-thalassemia carriers, with high HbA2 (>3.5%) values were considered possibly β-thalassemia carriers, respectively (13).

Genetic Analyses
According to the instructions (14). We used QIAamp DSP DNA Blood Mini Kit to extract DNA from blood. Genomic DNAs of subjects were extracted from peripheral blood lymphocytes by extraction kits according to the manufacturer’s instructions. Three known α-thalassemia deletion defects (−SEA/αα, −α3.7/αα, −α4.2/αα) were determined by the gap-polymerase chain reaction (Gap-PCR) technique. 17 known β-globin mutations was detected by PCR-reverse dot blot (PCR-RDB) assay. In order to detect unknown and rare β-globin mutations, β-globin gene of all the samples was directly sequenced.

| Mutation Type | Case (n) | Frequency (%) |
|---------------|----------|---------------|
| Heterozygote  |          |               |
| −SEA/αα      | 257      | 52.13         |
| −α3.7/αα     | 137      | 27.79         |
| −α4.2/αα     | 8        | 1.62          |
| Compound heterozygote | 81 | 16.43 |
| −SEA/αα+     | 10       | 2.03          |
| Total         | 493      | 100           |

α, normal production of the α-globin polypeptide chain; α+, no production of the α-globin polypeptide chain; α−, reduced production of the α-globin polypeptide chain.

RESULTS

The Characteristic of Thalassemia in Yunnan Province
During 2014 to 2018, 1,130 of the 3,539 suspected children were diagnosed thalassemia gene carriers with a carrying rate of 31.92% (1,130/3,539). Among them, α-thalassemia children were 43.63% (493/1,130), β-thalassemia children were 53.98% (610/1,130), children with both α- and β-thalassemia were 2.36% (27/1,130). Three α-globin gene deletion and five genotypes were detected in α-thalassemia children. Fifteen gene mutations and 30 genotypes were identified in β-thalassemia children (Tables 1–3).

The Prevalence and Mutation Spectrum of α-Thalassemia
13.93% (493/3,539) children were diagnosed as being carriers of α-thalassemia (Table 1), three known mutations in the α-globin gene were found, in which the −SEA/αα deletion was the most prevalent genotype, accounting for over one half of the mutations (52.13%), followed by −α3.7/αα (27.79%), hemoglobin H disease (18.46%), and −α4.2/αα (1.62%). Meanwhile, five α-globin genotypes were detected, including 402 children (81.54%) with heterozygous mutations and 91 children (18.46%) with compound heterozygous mutations. Overall, the first three mutations accounted for 98.38% of all α-globin gene mutations.

The Prevalence and Mutation Spectrum of β-Thalassemia
17.24% (610/3,539) children were carriers of the β-thalassemia, as shown in Table 2. Genetic analysis revealed 15 kinds of mutations and 30 genotypes, including 508 (83.29%) heterozygotes, 82 (13.44%) compound heterozygotes, and 20 (3.29%) homozygotes. The first five most common mutations are CD17 (A>T) (29.51%), CD41–42 (−TTCT) (27.87%), IVS-II-654 (C>T) (14.92%), CD26 (6.89%), and CD26/CD27 (2.62%) accounting for 81.81% of β-thalassemia genotypes. In addition, we founded two particularly rare mutations CD34 (TGG → TAG) and Int in Chinese populations.
TABLE 2 | Frequency of β-thalassemia mutations in children in the Yunnan province.

| Mutation          | Type    | Case (n) | Frequency (%) |
|-------------------|---------|----------|---------------|
| Heterozygote      |         | 508      | 83.29         |
| CD17/αN           | β²β¹N   | 180      | 29.51         |
| CD41–42/β¹N       | β²β¹N   | 170      | 27.87         |
| IVS-II-654/β¹N    | β²β¹N   | 91       | 14.92         |
| CD26/β¹N          | β²β¹N   | 42       | 6.89          |
| CD71–72/β¹N       | β²β¹N   | 15       | 2.46          |
| IVS-I/II-654      | β²β¹N   | 4        | 0.66          |
| −28/β¹N           | β²β¹N   | 3        | 0.49          |
| −29/β¹N           | β²β¹N   | 1        | 0.16          |
| CD34/β¹N          |         | 1        | 0.16          |
| CD43/β¹N          |         | 1        | 0.16          |
| Compound heterozygote |     | 82      | 13.44         |
| CD26/CD27         | β²β²    | 16       | 2.62          |
| CD41–42/CD17      | β²β²    | 15       | 2.46          |
| CD26/IVS-II-654   | β²β⁺     | 11      | 1.80          |
| CD41–42/CD26      | β²β⁺     | 10      | 1.64          |
| CD17/–28          | β²β⁺     | 5       | 0.82          |
| CD27/CD28         | β²β⁺     | 4       | 0.66          |
| CD17/IVS-II-654   | β²β⁺     | 4       | 0.66          |
| CD41–42/IVS-II-654| β²β⁺  | 3       | 0.49          |
| CD41–42/CD43      | β²β⁺     | 3       | 0.49          |
| CD14–15/β¹N       | β²β¹N   | 3       | 0.49          |
| CD26/–28          | β²β⁺     | 1       | 0.16          |
| CD26/CD43         | β²β⁺     | 1       | 0.16          |
| CD71–72/CD26      | β²β⁺     | 1       | 0.16          |
| CD41–42/IVS-I     | β²β⁺     | 1       | 0.16          |
| INT/β¹N           | β²β¹N   | 1       | 0.16          |
| Homozygote        |         | 20       | 3.29          |
| CD17/CD17         | β²β²    | 13      | 2.13          |
| CD41–42/CD41–42   | β²β²    | 4       | 0.66          |
| IVS-II-654/IVS-II-654| β²β²  | 2       | 0.33          |
| CD26/CD26         | β²β⁺     | 1       | 0.16          |
| Total             |         | 610      | 100.00        |

β²⁺, normal production of the β-globin polypeptide chain; β²⁻, no production of the β-globin polypeptide chain; β⁺⁺, impaired production of the β-globin polypeptide chain; β⁰, Codon26.

The Prevalence and Mutation Spectrum of Both α- and β-Thalassemia

The distributions of mutations and hematological features are shown in Table 3. 0.76% (27/3,539) children were both α- and β-thalassemia, 15 genotypes were discovered. The top four genotypes of thalassemia were −SEA/αα, CD17/N (14.81%); −SEA/αα, α²⁺/αα, CD26/N (14.81%); −α²⁺/αα, CD17/N (11.11%); −SEA/αα, CD14–42/N (11.11%).

TABLE 3 | Distribution of carriers of both α- and β-thalassemia genotypes in children in Yunnan province.

| Mutation          | Type    | Case (n) | Frequency (%) |
|-------------------|---------|----------|---------------|
| −SEA/αα, CD17/β¹N | α²⁻/αα  | 4        | 14.81         |
| −SEA/αα, α²⁺/αα   | β²⁻β⁰   | 4        | 14.81         |
| −α²⁺/αα, CD17/β¹N | α²⁻/αα  | 3        | 11.11         |
| −SEA/αα, CD41–42/β¹N| α²⁻/αα  | 3        | 11.11         |
| −SEA/αα, CD26/β¹N | α²⁻/αα  | 2        | 7.41          |
| −α²⁺/αα, CD41–42/β¹N| α²⁻/αα  | 2        | 7.41          |
| −α²⁺/αα, CD41–42/CD17| α²⁻/αα  | 1        | 3.70          |
| −α²⁺/αα, CD17/β¹N | α²⁻/αα  | 1        | 3.70          |
| −SEA/αα, CD41–42/CD17| α²⁻/αα  | 1        | 3.70          |
| −SEA/αα, CD43/IVS-II-654| α²⁻/αα  | 1        | 3.70          |
| −α²⁺/αα, CD41–42/β¹N| α²⁻/αα  | 1        | 3.70          |
| −α²⁺/αα, CD17/–28 | α²⁻/αα  | 1        | 3.70          |
| −α²⁺/αα, CD41–42/CD17| α²⁻/αα  | 1        | 3.70          |
| −α²⁺/αα, CD26/β¹N | α²⁻/αα  | 1        | 3.70          |
| Total             |         | 27       | 100.00        |

α, normal production of the α-globin polypeptide chain; α²⁻, no production of the α-globin polypeptide chain; α²⁺, reduced production of the α-globin polypeptide chain. β²⁻, normal production of the β-globin polypeptide chain; β²⁻, no production of the β-globin polypeptide chain; β⁺⁺, impaired production of the β-globin polypeptide chain; β⁰, Codon26.

Yunnan province, the southwestern of China. Among 3,539 suspected children, 1,130 were diagnosed with thalassemia, 493 had α-thalassemia, 610 had β-thalassemia, and 27 were carriers with both α- and β-thalassemia. −SEA/αα was the most frequent genotype in α-thalassemia and CD17 was the most frequent genotype in β-thalassemia.

It is reported that about 7% of the world’s population are carriers of a globin gene mutation (7). In mainland China the overall prevalence of α-, β-, and α + β-thalasemia was 7.88, 2.21, and 0.48%, respectively (15). Our study showed α-, β-, and α + β-thalasemia was 13.93, 17.24, and 0.76%, respectively (Tables 1–3). Compared with the overall prevalence, the higher thalassemia prevalence in Yunnan province showed in our study. The reason may be concerned to the selection of the subjects who detected thalassemia gene mainly due to microcytic hypochromic anemia, hemolytic anemia of unknown origin, not random crowd, which is also the limitation of this study. In our study, there was more β-thalassemia children than α-thalassemia children which is similar to some studies of the thalassemia in China (16).

Previous studies have shown that α-thalassemia is mainly caused by three types of gene deletions, including the Southeast Asian deletion (−SEA/αα), right deletion (−α²⁺/αα), and the left deletion (−α²⁻/αα), which account for 60.81% of thalassemia patients (1). In this study, −SEA/αα was the most common α-thalassemia genotype account for 52.13%, followed by −α²⁺/αα (Table 1). This result is consistent with the genotypes of Yulin and Fuzhou areas in China (17, 18), which is also similar to Lao Loun Group in the Lao People’s Democratic Republic (19). Additionally, our study showed a high prevalence of α−SEA/αα and β⁻ mutations account for 16.43%, which was

DISCUSSION

In the present study, we have investigated the prevalence and mutation characteristics of thalassemia among the children in
higher than the incidence of the $-\alpha^{4.2}/\alpha\alpha$ (0.95%; Table 1). This result is different to the other southern regions in China (20).

In contrast to $\alpha$, $\beta$-thalassemia carriers are more often caused by point mutations. At present, more than 300 different $\beta$-globin gene mutations have been reported around the world (4). In China, more than 40 $\beta$-globin gene mutations have been founded, the common mutations are CD41–42, CD17 (A>T), $-28$ (A>G), and IVS-II-654 (C>T) that account for 86.0% of the cases studied (6). The spectrums of the $\beta$-thalassemia gene mutations is diverse in different areas (7). Our data showed that 15 different mutations and 30 genotypes were identified in the 610 $\beta$-thalassemia carriers. CD17 (A>T) is the most common $\beta$-thalassemia mutation (Table 2), which consist with Guizhou province (21). However, CD41–42 is the most frequent mutation in Guangxi and Hainan in the southern of China (17, 22). While IVS-II-654 were the principal mutations of $\beta$-thalassemia in Meizhou city of Guangdong Province (23). In contrast to our study, it is also reported that CD26 ($\beta^{E}$) is the most frequent mutation in Yunnan region (11). The difference was probably due to the difference of samples and subjects. Additionally, two rare mutations of CD34 and Int were identified in the children according to our knowledge (Table 2), which was the first report of the abnormal hemoglobin in the Chinese population. This results show that there is a great heterogeneity of genotype in $\beta$-thalassemia in this area. Yunnan is a multi-ethnic province, thus the heterogeneity were caused by population admixture, marriage patterns, and migrations.

CONCLUSION

Our data suggested that the prevalence and gene mutation spectrum of thalassemia display obviously heterogeneity among children in Yunnan Province. The findings extended the mutation spectrum of thalassemia in this region, which provided the valuable information for premarital and pre-pregnancy screening, prenatal diagnostic services, and designing appropriate prevention programs to control the incidence of severe thalassemia for future in this area.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/supplementary material.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Kunming Children's Hospital research ethics committee. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

T-LH, T-YZ, and Y-HY designed the study. XT, Q-LL, C-YS, B-HS, C-HY, and NL performed data collection. T-LH and X-WZ analyzed the data and wrote the manuscript.

ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (grant no: 81901118); the Medical reserve talents training plan of Yunnan Health and Family Planning Commission (grant no: H-20170707), and the Medical and health science and technology plan of Kunming Health and Family Planning Commission (grant no: 2018-06-01-014), and the Kunming science and technology plan project (grant no: 2019-1-S-25318000001521), and the 17th batch of training plan for young and middle-aged academic and technical leaders and reserve candidates in Kunming.

REFERENCES

1. Koh DXR, Raja Sabudin RZA, Mohd Yusoff M, Hussin NH, Ahmad R, Othman A, et al. Molecular characterisation of $\alpha$ and $\beta$-thalassaemia among indigenous senoi orang asli communities in peninsular Malaysia. Ann Hum Genet. (2017) 81:205–12. doi: 10.1111/ahg.12201

2. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. (2018) 391:155–67. doi: 10.1016/S0140-6736(17)31822-6

3. Dong BQ, Chen BY, Liang QY, He S, Lyu W, Liu BT, et al. Study on the characteristics of major birth defects in 1.69 million cases of fetus in Guangxi Zhuang autonomous region. Zhonghua Liu Xing Bing Xue Za Zhi. (2019) 40:1554–9. doi: 10.3768/cmaj.issn.0254-6450.2019.12.009

4. Yao XY, Yu J, Chen SP, Xiao JW, Zheng QC, Liu HY, et al. Prevalence and genetic analysis of $\alpha$-thalassemia and $\beta$-thalassemia in Chongqing area of China. Gene. (2013) 532:120–4. doi: 10.1016/j.gene.2013.09.031

5. Choudhry VP. Quality of life in thalassemia major. Indian J Pediatr. (2018) 85:957–8. doi: 10.1007/s12098-018-2792-z

6. Li CK. New trend in the epidemiology of thalassaemia. Best Pract Res Clin Obstet Gynaecol. (2017) 39:16–26. doi: 10.1016/j.bpobgyn.2016.10.013

7. Tang W, Zhang C, Lu F, Tang J, Lu Y, Cui X, et al. Spectrum of $\alpha$-thalassemia and $\beta$-thalassemia mutations in the Guilin Region of southern China. Clin Biochem. (2015) 48:1068–72. doi: 10.1016/j.clinbiochem.2015.06.008

8. Zhao P, Wu H, Zhong Z, Lan L, Zeng M, Lin H, et al. Molecular prenatal diagnosis of $\alpha$ and $\beta$ thalassemia in pregnant Hakka women in southern China. J Clin Lab Anal. (2018) 32:1–6. doi: 10.1002/jcla.22306

9. Xiong F, Sun M, Zhang X, Cai R, Zhou Y, Lou J, et al. Molecular epidemiological survey of haemoglobinopathies in the Guangxi Zhuang autonomous region of southern China. Clin Genet. (2010) 78:139–48. doi: 10.1111/j.1399-0004.2010.01430.x

10. Yao H, Chen X, Lin L, Wu C, Fu X, Wang H, et al. The spectrum of $\alpha$- and $\beta$-thalassemia mutations of the Li people in Hainan Province of China. Blood Cells Mol Dis. (2014) 53:16–20. doi: 10.1016/j.bcmd.2014.01.003

11. Zhang J, Zhu BS, He J, Zeng XH, Su J, Xu XH, et al. The spectrum of $\alpha$- and $\beta$-thalassaemia mutations in Yunnan Province of Southwestern China. Hemoglobin. (2012) 36:464–73. doi: 10.3109/03630269.2012.717327

12. Wu H, Wang H, Lan L, Zeng M, Zhao P. Invasive molecular prenatal diagnosis of alpha and beta thalassemia among Hakka pregnant women. Medicine. (2018) 97:52–8. doi: 10.1097/MD.0000000000013557

13. Zhao P, Wu H, Weng R. Molecular analysis of hemoglobinopathies in a large ethnic Hakka population in southern China. Medicine (Baltimore). (2018) 97:e13034–7. doi: 10.1097/MD.0000000000013034

14. Yang Z, Cui Q, Zhou W, Qiu L, Han B. Comparison of gene mutation spectrum of thalassemia in different regions of China and Southeast Asia. Mol Genet Genomic Med. (2019) 7:e680–9. doi: 10.1002/mg3.680
15. Lai K, Huang G, Su L, He Y. The prevalence of thalassemia in mainland China: evidence from epidemiological surveys. Sci Rep. (2017) 7:920–44. doi: 10.1038/s41598-017-00967-2

16. Zhu Y, Shen N, Wang X, Xiao J, Lu Y. α and β-thalassemia mutations in Hubei area of China. BMC Med Genet. (2020) 21:6–11. doi: 10.1186/s12881-019-0925-5

17. He S, Li J, Li DM, Yi S, Lu X, Luo Y, et al. Molecular characterization of α- and β-thalassemia in the Yulin region of Southern China. Gene. (2018) 655:61–4. doi: 10.1016/j.gene.2018.02.058

18. Cao PJ, Chen LY, Jiang LL, Yang Y, Chen ST, Huang CL, et al. Analysis of gene mutation types of thalassemia in Fuzhou area of China. Zhongguo Shi Yan Xue Ye Xue Za Zhi. (2019) 27:893–8. doi: 10.19746/j.cnki.issn.1009-2137.2019.03.041

19. Phannany S, Chanprasert S, Munkongdee T, Svasti S, Loecharoenkiet K. Molecular prevalence of thalassemia and hemoglobinopathies among the Lao Loun Group in the Lao People’s Democratic Republic. Int J Lab Hematol. (2019) 41:650–6. doi: 10.1111/ijlh.13080

20. He J, Zeng H, Zhu L, Li H, Shi L, Hu L. Prevalence and spectrum of thalassaemia in Changsha, Hunan province, China: discussion of an innovative screening strategy. J Genet. (2017) 96:327–32. doi: 10.1007/s12041-017-0779-6

21. Huang SW, Liu XM, Li GF, Su L, Wu X, Wang RL. Spectrum of β-thalassemia mutations in Guizhou Province, PR China, including first observation of codon 121 (GAA>TAA) in Chinese population. Clin Biochem. (2013) 46:1865–8. doi: 10.1016/j.clinbiochem.2013.09.014

22. Li M, Xiang SH, Ding Y, Liu WW, Xu YY, Bo J. Genotype analysis of patients with thalassemia in Sanya area of Hainan province in China. Zhongguo Shi Yan Xue Ye Xue Za Zhi. (2018) 26:1146–50. doi: 10.7534/j.issn.1009-2137.2018.04.033

23. Wu H, Zhu Q, Zhong H, Yu Z, Zhang Q, Huang Q. Analysis of genotype distribution of thalassemia and G6PD deficiency among Hakka population in Meizhou city of Guangdong province. J Clin Lab Anal. (2019) 3:e23140–9. doi: 10.1002/jcla.23140

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Huang, Zhang, Song, Lin, Sang, Li, Yang, Li, Tian, Yang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.